"Beginning next year, we expect AR101 to generate revenue for the company with unadjusted potential sales of $1.2B by 2024, vs. no product revenues currently," Credit Suisse said in a note.
"From an M&A perspective, we believe that Aimmune is an acquisition target from a position of strength, as it has an asset that is likely to be approved near-term," the analyst said. "A company could acquire prior to approval and shape the commercial trajectory of the asset."
Price: 20.24, Change: +0.59, Percent Change: +3.00
|--Fed's Beige Book:Outlook Positive Even With Concer...|
|Sector Update: Tech Stocks Posting Small Gains|
|Steelcase Down 6% After Director Sells Company Shares|
|Sector Update: Consumer Stocks Falling in Recent Trade|
|Fransesca's Rallies After Cross River Capital Acquir...|